Afficher la notice abrégée

dc.contributor.editorChackrewarthy, Sureka
dc.date.accessioned2021-04-20T15:40:14Z
dc.date.available2021-04-20T15:40:14Z
dc.date.issued2012
dc.identifierONIX_20210420_9789535108917_1686
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/66328
dc.description.abstractThe progression from normal glucose tolerance (NGT) to type 2 diabetes involves intermediate stages of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), also known as prediabetes. The pathophysiology underlying the development of these glucose metabolic alterations is multifactorial, leading to an alteration in the balance between insulin sensitivity and insulin secretion. Our knowledge of the molecular basis of the signaling pathways mediating the various physiologic effects of insulin is steadily advancing. New substrates and signaling molecules have been identified and potential mechanisms involved in the pathophysiology of type 2 diabetes have been revealed. This book summarises the current state of knowledge on the pathophysiology underlying the progression from normal glucose tolerance to type 2 diabetes and therapeutic advances in the improvement of glycaemic control in prediabetic and diabetic states.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJG Endocrinologyen_US
dc.subject.otherEndocrinology
dc.titleGlucose Tolerance
dc.typebook
oapen.identifier.doi10.5772/2916
oapen.relation.isPublishedBy78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6
oapen.relation.isbn9789535108917
oapen.relation.isbn9789535170518
oapen.imprintIntechOpen
oapen.pages256


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/3.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/3.0/